Alphamab Oncology (9966) Fundamentals 2026 — Revenue Analysis | SniperIQ
Alphamab Oncology (9966) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$7.3B, trading at HK$7.58 on the HKSE. This SniperIQ fundamentals page covers Alphamab Oncology's valuation, profitability (net margin -19.9%), revenue (¥552M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alphamab Oncology's market cap?
Alphamab Oncology (9966) has a market capitalization of approximately HK$7.3B, trading at HK$7.58 on the HKSE. Market cap moves with the live share price.
What is Alphamab Oncology's P/E ratio?
Alphamab Oncology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alphamab Oncology?
Alphamab Oncology runs a net profit margin of -19.9%, a gross margin of 83.0%, and an operating margin of -26.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alphamab Oncology generate?
Alphamab Oncology reported revenue of ¥552M for fiscal year 2025, with net income of -¥111M and earnings per share (EPS) of -0.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alphamab Oncology pay a dividend?
Alphamab Oncology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Alphamab Oncology financially healthy?
Alphamab Oncology carries a debt-to-equity ratio of 0.07x and a current ratio of 5.67x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alphamab Oncology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alphamab Oncology (9966) the key facts are: market cap HK$7.3B, revenue ¥552M, 52-week range 6.23-15.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alphamab Oncology's full fundamentals live
Get Alphamab Oncology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.